This website uses cookies to ensure you get the best experience on our website. Privacy Policy
UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
  • Transformative Evidence
    • mCRPC
      • The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
      • PROfound
      • VISION Trial
    • mHSPC
      • ARASENS Trial
    • nmCRPC
      • ARAMIS Trial
    • PSMA PET Imaging
      • CONDOR Trial
      • OSPREY Trial
    • Bladder Cancer
      • Bladder Cancer Detection
  • Centers of Excellence
    • Urologic Oncology
      • Left Group
        • Health Policy
          • Health Policy
            Ruchika Talwar, MD
        • Bladder Cancer
          • Bladder Cancer
            Ashish Kamat, MD
          • Advanced Bladder Cancer
            Petros Grivas, MD
        • Kidney Cancer
          • Advanced Kidney Cancer
            Pedro Barata, MD, MSc
          • Kidney Cancer Today
            Sumanta (Monty) Kumar Pal, MD
            Jaime Landman, MD
      • Prostate Cancer
        • Advanced Prostate Cancer
          Alicia Morgans, MD, MPH
        • CRPC with Bone Metastases
          Rana R. McKay, MD
        • Imaging Center
          Phillip Koo, MD
        • Localized Prostate Cancer
          Matthew R. Cooperberg, MD, MPH
        • mHSPC
          Alicia Morgans, MD, MPH
        • nmCRPC
          Alicia Morgans, MD, MPH
        • PSMA-Targeted Therapy
      • Translational Prostate Cancer
        • Women in Science
          Andrea Miyahira, Ph.D
      • Upper Tract Urothelial Carcinoma
        • Upper Tract Urothelial Carcinoma
          Sam S. Chang, MD, MBA
      • TESTICULAR, PENILE & RARE GU MALIGNANCIES
        • Testicular, Penile, and Rare GU Malignancies
    • Pelvic Health & Reconstruction
      • Bladder Health
        Diane K. Newman, DNP, ANP-BC, FAAN
      • Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
        Stephen R. Kraus, MD
      • Urologic Catheters (Includes CAUTI)
        Diane K. Newman, DNP, ANP-BC, FAAN
  • Videos
    • Exclusives
      • Conferences
      • Exclusive Collaborations
      • Independent Education
      • Covid-19
      • The Prostate Cancer Foundation
    • Urologic Oncology
      • Prostate Cancer
      • Bladder Cancer
      • Kidney Cancer
      • Upper Tract Urothelial Tumors
      • Pelvic Health & Reconstruction
      • Endourology
      • Testicular Cancer
      • Health Policy in Urological Diseases
  • Clinical Trials
    • From the Editor
      • Search Clinical Trials
    • Trials in Progress
      • DORA - PCCTC
      • IRONMAN - PCCTC
      • PROMISE - PCCTC
      • SPLASH Trial
      • Oral EPI-7386
  • Articles
    • Urology (benign and malignant)
      • Urologic Oncology
      • Men's Health
      • Endourology & Stones
      • Pediatric Urology
      • COVID-19 and Genitourinary Cancers
    • Pelvic Health
      • Pelvic Health & Reconstruction
  • Conference Coverage
    • Recent Conferences
      • SUO 2022
      • ASCO GU 2023
      • EAU 2023
    • All Conferences
      • View All
  • PCF
  1. UroToday Home
  2. Recent Abstracts
  3. Urologic Oncology
  4. Prostate Cancer

Conferences

Recent Abstracts
ASCO GU 2023: Barriers to Guideline-Concordant Use of Bone Modifying Agents for Prostate Cancer February 16, 2023
ASCO GU 2023: Geographic Variation of Decipher® Genomic Classifier in Patients with Early Prostate Cancer February 16, 2023
ASCO GU 2023: Effect of Equal Access to Care on Prostate Cancer Progression in Minority Patients February 16, 2023
ASCO GU 2023: LuCAB: A Phase I/II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with mCRPC February 16, 2023
ASCO GU 2023: Effect of Cerebral Dopamine Metabolism Genetic Polymorphism on Patient-Reported Quality-of-Life (QOL): An Analysis of the E3805 CHAARTED Trial February 16, 2023
ASCO GU 2023: The CONFIDENT-P Trial: Clinical Implementation of Artificial Intelligence Assistance in Prostate Cancer Pathology February 16, 2023
ASCO GU 2023: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study February 16, 2023
ASCO GU 2023: Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE): ECOG-ACRIN EA8191 February 16, 2023
ASCO GU 2023: Development and Validation of a Multi-Institutional Nomogram of Outcomes for PSMA-PET–based Salvage Radiotherapy in Recurrent Prostate Cancer February 16, 2023
ASCO GU 2023: Real World Prospective Evaluation of Clinical Outcomes in Patients with Non-Metastatic Castrate Resistant Prostate Cancer Treated with Darolutamide February 16, 2023
ASCO GU 2023: Baseline Characteristics Associated with PSA Progression-Free Survival in Patients (Pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO Study (AFT-19) February 16, 2023
ASCO GU 2023: Long-Term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients with nmCRPC from the ARAMIS Rollover Study February 16, 2023
ASCO GU 2023: Geographic Variation in Utilization of Doublet Therapy for Metastatic Prostate Cancer February 16, 2023
ASCO GU 2023: Changes in Planned Disease Management after Piflufolastat F18 PET/CT in Men with Biochemically Recurrent Prostate Cancer and Low PSA Levels: A Secondary Analysis of Results from the CONDOR Study February 16, 2023
ASCO GU 2023: Discussion of Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker and the FORMULA-509 Trial of Post-Operative Salvage Radiotherapy Post-Radical Prostatectomy February 16, 2023
ASCO GU 2023: A Phase II Trial Modifying Metabolic Syndrome and Cardiovascular Risk for Patients with Prostate Cancer on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring (ProTrio) February 16, 2023
ASCO GU 2023: EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA-617 Therapy Versus 177Lu-PSMA-617 in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC; ANZUP 2001) February 16, 2023
ASCO GU 2023: A Multi-Center, Prospective, Observational Study of Patients with Prostate Cancer Being Treated with Relugolix: OPTYX February 16, 2023
ASCO GU 2023: A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR) February 16, 2023
ASCO GU 2023: Increased Utilization of Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapy (PSMA-TRT) in African American (AA) Patients at an Academic Medical Center February 16, 2023
Page 13 of 507
  • Start
  • Prev
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next
  • End
  • About UroToday
  • Journals
  • Calendar
  • Editorial and Advertising Guidelines
  • Editors and Contributors
  • FAQs
  • Privacy Policy
  • Terms of Use
Follow UroToday

COPYRIGHT © 2002 - 2023 DIGITAL SCIENCE PRESS, LLC

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free